Disclaimer: This is an early beta prototype. If you find any error, with data or functionality, please let us know via this page.
Registration date period
Results ordered by trial registration date, descending.
  1. Prevenar Study conducted in Russia

    Registration date:
    Status:
    Unknown
    Recruitment status:
    Unknown
    Source name:
    EU Clinical Trials Register

    The primary objective is to estimate the incidence of febrile reactions of ≥38 to ≤39°C; >39 to ≤40°C; >40°C occurring within 2 days following vaccination with Prevenar (PCV-7) coadministered with...

    Conditions:
    • Infants from 3 months up to 23 months of age who may benefit from active immunization against disease caused by Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F (including sepsis, meningitis, pneumonia, bacteraemia and acute otitis media) and who would be scheduled to receive Prevenar PCV-7
    Interventions:

    Unknown

  2. Clinical study to investigate the efficacy, safety and tolerability of Naloxone in patients with opioid induced constipation Klinické skúšanie s cieľom preskúmať účinnosť, bezpečnosť a znášanlivosť Nalóxonu u pacientov so zápchou vyvolanou opioidmi

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Unknown
    Source name:
    EU Clinical Trials Register

    To assess the efficacy of Naloxone HCl PR Tablets administered twice daily at TDD of 24 mg and 48 mg over placebo in the treatment of opioid induced constipation (OIC) in terms of overall complete...

    Conditions:
    • Opioid induced constipation
    Interventions:
    • Naloxone Hydrochloride Prolonged Release Tablets
  3. WHITE 7 - WHISH – Wound Healing in Surgery for Hip fractures

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Not recruiting
    Source name:
    ISRCTN

    Background and study aims Hip fractures affect 70 000 patients per year in the UK, and it is predicted that 100 000 people will suffer a hip fracture in the UK by 2020. Almost all patients undergo...

    Conditions:
    • Specialty: Injuries and emergencies, Primary sub-specialty: Injuries and emergencies; UKCRC code/ Disease: Injuries and Accidents/ Injuries to the hip and thigh, Infection/ Other infectious diseases
    Interventions:

    Unknown

  4. Study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of MOTREM in patients with septic shock. Estudio de evaluación de la seguridad, tolerabilidad, farmacocinética y farmacodinámica de MOTREM en pacientes con shock séptico

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Unknown
    Source name:
    EU Clinical Trials Register

    To evaluate the safety and tolerability of MOTREM in patients with septic shock Evaluar la seguridad y tolerabilidad de MOTREM en pacientes con choque séptico.

    Conditions:
    • Septic shock
    • Choque Séptico
    Interventions:
    • MOTREM
  5. Pancreatic replacement therapy and glycaemic control in diabetes

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Recruiting
    Source name:
    ISRCTN

    Background and study aims Diabetes is a common chronic condition. About 6% of the UK population already have either type 1 diabetes (T1DM) or type 2 diabetes (T2DM), and one in ten adults are at risk...

    Conditions:
    • Specialty: Diabetes, Primary sub-specialty: Both; UKCRC code/ Disease: Metabolic and Endocrine/ Diabetes mellitus
    Interventions:
    • Creon
  6. A Clinical trial to evaluate safety, and effectiveness of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis. Estudio para evaluar la seguridad y eficacia de selonsertib en pacientes con esteatohepatitis no alcohólica (EHNA) y fibrosis en puentes (F3)

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Unknown
    Source name:
    EU Clinical Trials Register

    The primary objective of this study is: To evaluate whether SEL can cause fibrosis regression and reduce progression to cirrhosis and associated complications in subjects with NASH and bridging (F3)...

    Conditions:
    • Nonalcoholic steatohepatitis (NASH)
    • Esteatohepatitis no alcohólica (EHNA)
    Interventions:
    • Selonsertib
  7. A Clinical trial to evaluate safety, and effectiveness of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) Estudio para evaluar la seguridad y la eficacia de selonsertib en pacientes con cirrosis compensada debida a esteatohepatitis no alcohólica (EHNA)

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Unknown
    Source name:
    EU Clinical Trials Register

    The primary objective of this study is: To evaluate whether SEL can cause fibrosis regression and reduce associated complications in subjects with cirrhosis due to NASH. Objetivo principal:...

    Conditions:
    • Nonalcoholic steatohepatitis (NASH)
    • Esteatohepatitis no alcohólica (EHNA)
    Interventions:
    • Selonsertib
  8. A Randomized, Double-blind, Phase 2 Trial to assess how safe and how efficacious Lenvatinib is at two different starting doses (18 mg vs. 14 mg QD) when it is given in Combination with Everolimus (5 mg once a day ) in patients with Renal cancer that have already had one VEGF-Targeted Treatment Ensayo de fase 2, aleatorizado y doble ciego para evaluar la seguridad y la eficacia de lenvatinib en dos dosis iniciales diferentes (18 mg y 14 mg una vez al día) cuando se administra en combinación con everolimus (5 mg una vez al día) en pacientes con cáncer renal después de un tratamiento previo dirigido contra el VEGF

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Unknown
    Source name:
    EU Clinical Trials Register

    To assess whether a starting dose of lenvatinib 14 mg in combination with everolimus 5 mg once daily (QD) will provide comparable efficacy (based on objective response rate [ORR]at 24 weeks[ORR24W])...

    Conditions:
    • ADVANCED RENAL CELL CARCINOMA
    • Carcinoma renal avanzado
    Interventions:
    • LENVATINIB
    • Afinitor